Innate Pharma announces conference call and webcast for Full Year 2021 financial results
Number of shares and voting rights of Innate Pharma as of March 1, 2022
Number of shares and voting rights of Innate Pharma as of February 1, 2022
Innate Pharma to participate in upcoming investor conferences
Number of shares and voting rights of Innate Pharma as of January 1, 2022
Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans
Innate Pharma to participate in upcoming investor conferences
First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers
Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line recurrent or metastatic head and neck cancer at ESMO Immuno-Oncology 2021 Congress
Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress
